Subgroup analysis by baseline (BL) weight-associated parameters: A phase III study of liposomal irinotecan (nal-IRI)±-5fluorouracil/leucovorin (5-FU/LV) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) previously treated with gemcitabine-based (gem) therapy.

被引：0
|
作者：
Macarulla, Teresa Mercade
Hubner, Richard
Blanc, Jean-Frederic
Wang-Gillam, Andrea
Li, Chung-Pin
Bodoky, Gyorgy
Dean, Andrew Peter
Yanshen, Shan
Jameson, Gayle S.
Lee, Kyung-Hun
Chiu, Chang-Fang
Schwartsmann, Gilberto
Braiteh, Fadi S.
Cunningham, David
Chen, Li-Tzong
Von Hoff, Daniel D.
Mamlouk, Khalid Kevin
de Jong, Floris A.
Siveke, Jens T.
机构：
[1] Vall d Hebron Univ Hosp, Inst Oncol, Barcelona, Spain
[2] Christie NHS Fdn Trust, Manchester, Lancs, England
[3] CHU Bordeaux, Pole ADEN, Hop Haut Leveque, Bordeaux, France
[4] Washington Univ, Sch Med St Louis, St Louis, MO USA
[5] Taipei Vet Gen Hosp, Taipei, Taiwan
[6] Szent Laszlo Teaching Hosp, Budapest, Hungary
[7] St John God Hosp, Subiaco, WA, Australia
[8] Natl Cheng Kung Univ Hosp, Tainan, Taiwan
[9] Honor Hlth, Virginia G Piper Canc Ctr, Scottsdale, AZ USA
[10] Seoul Natl Univ Hosp, Seoul, South Korea
[11] China Med Univ First Hosp, Taichung, Taiwan
[12] Fed Univ, Porto Alegre, RS, Brazil
[13] Comprehens Canc Centers Nevada, Las Vegas, NV USA
[14] Royal Marsden NHS Fdn Trust, London, England
[15] Natl Hlth Res Inst, Natl Inst Canc Res, Tainan, Taiwan
[16] Ipsen Biosci Inc, Cambridge, MA USA
[17] Shire GmbH, Zug, Switzerland
[18] Univ Hosp Essen, West German Canc Ctr, Essen, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2018年 / 36卷 / 04期
关键词：
D O I：
10.1200/JCO.2018.36.4_suppl.410
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
410
引用
收藏
页数：1
相关论文
共 49 条
  • [21] Effects of nanoliposomal irinotecan (nal-IRI;MM-398) ± 5-Fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in NAPOLI-1: a phase 3 study in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy
    Siveke, J. T.
    Cubillo, A.
    Blanc, J. -F
    Melisi, D.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L. -T
    Becker, C.
    Mamlouk, K.
    Belanger, B.
    Yang, Y.
    de Jong, F.
    Hubner, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 259 - 259
  • [22] The prognostic value of baseline neutrophilto-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) for predicting clinical outcome in patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV.
    Wang-Gillam, Andrea
    Chen, Li-Tzong
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Lee, Kyung-Hun
    Cunningham, David
    Hubner, Richard
    Braiteh, Fadi S.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris A.
    Mody, Purvi D.
    Von Hoff, Daniel D.
    Siveke, Jens T.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [23] Characteristics of long-term survivors in a randomized phase III trial (NAPOLI-1) of patients with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with liposomal irinotecan (nal-IRI; MM-398)+5-FU/LV
    Wang-Gillam, Andrea
    Li, Chung-Pin
    Bodoky, Gyorgy
    Dean, Andrew
    Lee, Kyung-Hun
    Cunningham, David
    Hubner, Richard
    Siveke, Jens T.
    Braiteh, Fadi S.
    Pipas, J. Marc
    Belanger, Bruce
    de Jong, Floris
    Mody, Purvi D.
    Chen, Li-Tzong
    Von Hoff, Daniel D.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [24] Subgroup Analysis by Measurable Metastatic Lesion Number and Selected Lesion Locations at Baseline in NAPOLI-1: A Phase III Study of Liposomal Irinotecan +/- 5-Fluorouracil/Leucovorin in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Previously Treated With Gemcitabine-Based Therapy
    Bekaii-Saab, Tanios
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2018, 16 (03) : 10 - 12
  • [25] Efficacy of liposomal-irinotecan (nal-IRI) plus 5-fluorouracil/folinic acid (5-FU/LV) versus oxaliplatin plus fluoropyrimidines in previous gemcitabine treated pancreatic adenocarcinoma (PAC) patients (pts).
    Kieler, Markus
    Unseld, Matthias
    Bianconi, Daniela
    Scheithauer, Werner
    Prager, Gerald W.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [26] A phase 1/2, open -label, dose -expansion study of liposomal irinotecan (nal-IRI) plus 5-fluorouracil/leucovorin (5-FU/LV) and oxaliplatin (OX) in patients with previously untreated metastatic pancreatic cancer
    Wainberg, Z.
    Boland, P.
    Lieu, C.
    Dayyani, F.
    Macarulla, T.
    Zhang, B.
    Belanger, B.
    Moore, Y.
    Wang, T.
    Maxwell, F.
    Dean, A.
    ANNALS OF ONCOLOGY, 2019, 30
  • [27] Effects of nanoliposomal irinotecan (nal-IRI; MM-398) ± 5-fluorouracil and leucavorin (5-FU/LV) on quality of life (QoL) in patients (pts) with metastatic pancreatic adenocarcinoma (mPAC) previously treated with gemcitabine-based therapy: results from the phase 3 NAPOLI-1 study
    Melisi, D.
    Melisi, D.
    Siveke, J. T.
    Blanc, J.
    Von Hoff, D. D.
    Wang-Gillam, A.
    Chen, L.
    Becker, C.
    Mamlouk, K.
    De Jong, F.
    Hubner, R.
    ANNALS OF ONCOLOGY, 2016, 27
  • [28] Time course of selected treatment emergent adverse events (TEAEs) in NAPOLI-1: A phase 3 study of nal-IRI (MM-398) ± 5-fluorouracil and leucovorin (5-FU/LV) vs 5-FU/LV in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Hubner, R. A.
    Chen, L-T.
    Siveke, J. T.
    Li, C-P.
    Bodoky, G.
    Dean, A.
    Shan, Y-S.
    Jameson, G. S.
    Macarulla, T.
    Lee, K-H.
    Cunningham, D.
    Blanc, J-F.
    Chiu, C-F.
    Schwartsmann, G.
    Braiteh, F.
    Mamlouk, K.
    Belanger, B.
    de Jong, F.
    von Hoff, D. D.
    Wang-Gillam, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [29] Efficacy and safety of liposomal irinotecan (nal-IRI) plus fluorouracil (5-FU) and leucovorin (LV) versus 5-FU/LV alone for advanced biliary tract cancer (BTC) after progression on gemcitabine-based therapy: A pooled analysis of the NIFTY and NALIRICC trials
    Yoo, C.
    Saborowski, A.
    Hyung, J.
    Wenzel, P.
    Kim, I.
    Wege, H.
    Kim, K-P
    Folprecht, G.
    Ryoo, B-Y
    Schuett, P.
    Cheon, J.
    Goetze, T. O.
    Ryu, H.
    Lee, J. S.
    Vogel, A.
    ANNALS OF ONCOLOGY, 2024, 35 : S235 - S235
  • [30] Expanded analyses of NAPOLI-1: Phase 3 study of nal-IRI (MM-398), with or without 5-fluorouracil (5FU) and leucovorin (LV), versus 5-fluorouracil and leucovorin (5FU/LV), in metastatic pancreatic cancer (mPAC) previously treated with gemcitabine-based therapy
    Siveke, J. T.
    Chen, L-T
    Von Hoff, D. D.
    Li, C-P
    Wang-Gillam, A.
    Bodoky, G.
    Dean, A.
    Shan, Y-S
    Jameson, G.
    Macarulla, T.
    Lee, K-H
    Cunningham, D.
    Blanc, J-F
    Hubner, R. A.
    Chiu, C-F
    Schwartsmann, G.
    Braiteh, F.
    Moyo, V.
    Belanger, B.
    Bayever, E.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 170 - 170
12345